Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL

NCT06652165 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

DRUG: zanubrutinib combined with BEAM
DRUG: BEAM

Sponsor

Ruijin Hospital